nm 4103 section 4 radiopharmaceutical characteristics

25
NM 4103 Section 4 Radiopharmaceutic al Characteristics

Upload: river-eells

Post on 31-Mar-2015

234 views

Category:

Documents


1 download

TRANSCRIPT

Page 1: NM 4103 Section 4 Radiopharmaceutical Characteristics

NM 4103Section 4

Radiopharmaceutical

Characteristics

Page 2: NM 4103 Section 4 Radiopharmaceutical Characteristics

99mTc Sodium Pertechnetate

Eluted from 99Mo generator Tested for 99Mo and Al breakthrough Can be used for preparation of 99mTc-labeled

radipharmaceuticals (kits) or Used to image Thyroid and Meckel’s

diverticulum (without mixing in a kit)

Page 3: NM 4103 Section 4 Radiopharmaceutical Characteristics

99mTc Macroaggregated Albumin (MAA)

Preparation: – Heating HSA– Wash particles

Particles– Number: 1-12 million particles per mg – Shape: irregular– Size: 10-90 µm

Checked for particle size Vial and syringe should be aggitated Used for lung perfusion imaging

Page 4: NM 4103 Section 4 Radiopharmaceutical Characteristics

99mTc Phosphates (MDP, HDP)

Kit Preparation: – Add 99mTc to kit, mix

Weak chelates and tend to degrade with time– Prevented with tin and antioxidants

Used for bone imaging

Page 5: NM 4103 Section 4 Radiopharmaceutical Characteristics

99mTc Sulfur Colloid

Preparation:– Add acid– Heat in water bath

Particles– Size: 0.1 to 1 µm

Larger particles could be trapped in the lungs Used for imaging liver/spleen, bone marrow,

lymphoscintigraphy, GI bleed, and gastric emptying.

Page 6: NM 4103 Section 4 Radiopharmaceutical Characteristics

99mTc Pentetate (DTPA)

Preparation– Add 99mTc to kit, mix

Used for renal and aerosol lung imaging.

Page 7: NM 4103 Section 4 Radiopharmaceutical Characteristics

99mTc labeled Red Blood Cells

Preparation– In Vitro Method (Ultratag® kit)

Draw blood, add to vial of stannous citrate/acid citrate dextrose(acd). Add sodium hypochlorite. Add ACD. Add 99mTc and incubate.

– In Vivo Method Sn2+ injected into patient. Wait 20 minutes, then 99mTc

injected into patient

Used to image GI bleed, liver hemangioma, gated blood pool (MUGA)

Page 8: NM 4103 Section 4 Radiopharmaceutical Characteristics

99mTc Iminodiacetic Acid (IDA)

DISIDA (Hepatolite®) & Mebrofenin (Choletec®)

Preparation– Add 99mTc to kit, mix

Used for hepatobiliary imaging.

Page 9: NM 4103 Section 4 Radiopharmaceutical Characteristics

99mTc Hexamethylpropylene Amine Oxime (Ceretec®)

Preparation of 99mTc HMPAO – Add 99mTc to kit, mix

Should be used within 4 hours of preparation.

Used for brain imaging and labeling leukocytes

Page 10: NM 4103 Section 4 Radiopharmaceutical Characteristics

99mTc Sestamibi (Cardiolite®)

Preparation– Add 99mTc to kit– Heat in boiling water bath for 10 minutes.

Used for imaging cardiac perfusion, parathyroid adenomas and breast tumors (Miraluma®).

Page 11: NM 4103 Section 4 Radiopharmaceutical Characteristics

99mTc Tetrofosmin (Myoview®)

Preparation– Add 99mTc to kit, mix and incubate for 15 minutes.

Used for myocardial perfusion

Page 12: NM 4103 Section 4 Radiopharmaceutical Characteristics

99mTc MAG3

Preparation:– Add 99mTc to kit– Add filtered air (to oxidize excess Sn2+ )– Heat in water bath for 10 min– Cool for 15 min

Light sensitive

Used for imaging renal function

Page 13: NM 4103 Section 4 Radiopharmaceutical Characteristics

99mTc Neurolite®

Preparation:– Isotonic saline added to vial A– 99mTc added to vial B– Add vial A to B and incubate for 30 minutes

Used for Brain perfusion imaging

Page 14: NM 4103 Section 4 Radiopharmaceutical Characteristics

99mTc DMSA

Preparation:– Add 99mTc to kit vial– Incubate for 10 minutes

Light sensitive

Used for renal cortical imaging

Page 15: NM 4103 Section 4 Radiopharmaceutical Characteristics

99mTc Gluceptate

Preparation:– 99mTc addto kit vial – Incubate for 15 minutes

Used for renal imaging

Page 16: NM 4103 Section 4 Radiopharmaceutical Characteristics

131 I Sodium Iodide

Supplied in capsule or liquid Oral administration

Used for thyroid uptake measurement and thyroid treatment

Page 17: NM 4103 Section 4 Radiopharmaceutical Characteristics

123 I Sodium Iodide

Cyclotron produced Capsule or liquid Oral administration

Used for thyroid uptake measurement and thyroid imaging

Page 18: NM 4103 Section 4 Radiopharmaceutical Characteristics

123 I or 131 I MIBG

Preparation– 131I and MIBG is refluxed for 72 hrs– Cooled– Passed through anion exchange column

Used for imaging pheochromocytoma and for treatment of neuroblastoma

Page 19: NM 4103 Section 4 Radiopharmaceutical Characteristics

111 In DTPA

Preparation:– Adding dilute DTPA to solution of 111InCl3 in

acetate buffer, pH 5– Heat for 15 minutes in boiling water bath

Used for cisternography and gastric emptying (liquid phase)

Page 20: NM 4103 Section 4 Radiopharmaceutical Characteristics

133 Xenon

Noble gas and is chemically inert Produced by fission of 235U in the reactor

Shelf life is 14 days after calibration

Should be handled in a proper fumehood

Used for ventilation lung imaging

Page 21: NM 4103 Section 4 Radiopharmaceutical Characteristics

201 Tl Thallous Chloride

Cyclotron produced

Used for myocardial perfusion imaging

Page 22: NM 4103 Section 4 Radiopharmaceutical Characteristics

111 In Labeled Leukocytes

Blood is drawn– Heparin or ACD added as anticoagulant– Hetastarch added to enhance sedimentation

Leukocytes are separated– Sedimentation, centrifuge, washing

Labeled with 111In Oxine

Used for detecting infection or abscesses.

Page 23: NM 4103 Section 4 Radiopharmaceutical Characteristics

99mTc Labeled Leukocytes

Blood is drawn– Heparin or ACD added as anticoagulant– Hetastarch added to enhance sedimentation

Leukocytes are separated– Sedimentation, centrifuge, washing

Labeled with 99mTc HMPAO (Ceretec®)

Used for detecting inflammation, abscess or other infections (also Chrohn’s disease)

Page 24: NM 4103 Section 4 Radiopharmaceutical Characteristics

111In Prostascint®

Murine monoclonal antibody Preparation:

– 111InCl3 added to vial– Incubate for 30 mintues– Filtered to remove particulate matter

Used for primary or metastatic prostate cancer.

Page 25: NM 4103 Section 4 Radiopharmaceutical Characteristics

111In Petetreotide (OctreoScan®)

Radiolabeled Peptide Preparation:

– 111InCl3 added to reaction vial– Incubate for 30 minutes

Used for neuroendocrine tumors– Carcinoids, gastrinomas, neuroblastomas,

pituitary adenomas, medullary thyroid cancer